Jiangxi Synergy Pharmaceutical Co., Ltd.
SZSE:300636 Rapport sur les actions
Capitalisation boursière : CN¥3.8b
Jiangxi Synergy Pharmaceutical Bilan de santé
Santé financière contrôle des critères 5/6 Jiangxi Synergy Pharmaceutical possède un total de capitaux propres de CN¥2.3B et une dette totale de CN¥745.9M, ce qui porte son ratio d'endettement à 32.3%. Son actif total et son passif total sont CN¥3.3B et de CN¥985.7M. L'EBIT de Jiangxi Synergy Pharmaceutical est CN¥108.6M ce qui fait que son ratio de couverture des intérêts -7. Elle dispose de liquidités et de placements à court terme de CN¥308.0M.
Informations clés Ratio de couverture des intérêts -7x Argent liquide CN¥307.96m Fonds propres CN¥2.31b Total du passif CN¥985.72m Total des actifs CN¥3.30b
Mises à jour récentes de la santé financière
Afficher toutes les mises à jour
Third quarter 2024 earnings released: EPS: CN¥0.062 (vs CN¥0.054 in 3Q 2023) Oct 24
Investor sentiment deteriorates as stock falls 20% Oct 15
Jiangxi Synergy Pharmaceutical Co., Ltd. (SZSE:300636) Stock Rockets 43% But Many Are Still Ignoring The Company Oct 08
Jiangxi Synergy Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 24, 2024 Sep 30
Investor sentiment improves as stock rises 19% Sep 27
Second quarter 2024 earnings released: EPS: CN¥0.062 (vs CN¥0.068 in 2Q 2023) Aug 29
Jiangxi Synergy Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024 Jun 29
Is Jiangxi Synergy Pharmaceutical (SZSE:300636) A Risky Investment? Jun 28
Jiangxi Synergy Pharmaceutical's (SZSE:300636) Profits Appear To Have Quality Issues May 01
Jiangxi Synergy Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2023 Apr 27
Jiangxi Synergy Pharmaceutical Co., Ltd.'s (SZSE:300636) 41% Share Price Surge Not Quite Adding Up Apr 27
Jiangxi Synergy Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024 Apr 26
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Apr 25
Investor sentiment improves as stock rises 17% Apr 11
Jiangxi Synergy Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024 Mar 30
Investor sentiment deteriorates as stock falls 17% Jan 31
Jiangxi Synergy Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 25, 2024 Dec 29
Third quarter 2023 earnings released: EPS: CN¥0.054 (vs CN¥0.094 in 3Q 2022) Oct 26
Jiangxi Synergy Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 26, 2023 Sep 30
Second quarter 2023 earnings released: EPS: CN¥0.068 (vs CN¥0.05 in 2Q 2022) Aug 29 Jiangxi Synergy Pharmaceutical Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 24 May 2023
First quarter 2023 earnings released: EPS: CN¥0.095 (vs CN¥0.087 in 1Q 2022) Apr 24
High number of new and inexperienced directors Nov 16
Third quarter 2022 earnings released: EPS: CN¥0.094 (vs CN¥0.078 in 3Q 2021) Oct 28
Investor sentiment improved over the past week Oct 17
Second quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.072 in 2Q 2021) Aug 28
Jiangxi Synergy Pharmaceutical Co., Ltd. Announces Final Cash Dividend on A Shares for 2021, Payable on 05 July 2022 Jun 30
Investor sentiment deteriorated over the past week May 20
Jiangxi Synergy Pharmaceutical Co., Ltd. Approves Final Dividend for 2021 May 18
Jiangxi Synergy Pharmaceutical Co., Ltd. Proposes Final Dividend for 2021 Apr 27
High number of new and inexperienced directors Apr 27
Investor sentiment deteriorated over the past week Apr 01
Investor sentiment improved over the past week Mar 14
Investor sentiment improved over the past week Dec 17
Third quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.091 in 3Q 2020) Oct 31
Investor sentiment improved over the past week Aug 26
Second quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.13 in 2Q 2020) Aug 09
Jiangxi Synergy Pharmaceutical Co., Ltd. Approves Dividend for 2020 Apr 26
Full year 2020 earnings released: EPS CN¥0.54 (vs CN¥0.38 in FY 2019) Apr 03
Jiangxi Synergy Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Apr 02, 2021 Feb 24
Investor sentiment improved over the past week Feb 22
Investor sentiment improved over the past week Jan 21
Full year 2020 earnings released: EPS CN¥0.56 Jan 16
New 90-day low: CN¥22.14 Jan 04
New 90-day low: CN¥26.06 Dec 09
New 90-day low: CN¥28.54 Nov 19
New 90-day low: CN¥31.21 Oct 28
Third quarter earnings released Oct 28
Jiangxi Synergy Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 27, 2020 Oct 20
Earnings released Aug 27
Jiangxi Synergy Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020 Aug 11
Analyse de la situation financière
Passif à court terme: Les actifs à court terme de 300636 ( CN¥995.4M ) dépassent ses passifs à court terme ( CN¥536.4M ).
Passif à long terme: Les actifs à court terme de 300636 ( CN¥995.4M ) dépassent ses passifs à long terme ( CN¥449.3M ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: Le ratio dette nette/capitaux propres de 300636 ( 19% ) est considéré comme satisfaisant .
Réduire la dette: Le ratio d'endettement de 300636 est passé de 18.4% à 32.3% au cours des 5 dernières années.
Couverture de la dette: La dette de 300636 est bien couverte par le flux de trésorerie opérationnel ( 29.5% ).
Couverture des intérêts: 300636 gagne plus d'intérêts qu'il n'en paie, donc la couverture des paiements d'intérêts n'est pas un problème.
Découvrir des entreprises saines Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
